1.Sorkin EM., Markham A. Cilostazol. Drugs Aging. 1999. 14:63–71.
Article
2.Horie N., Kaminogo M., Izumo T., Hayashi K., Tsujino A., Nagata I. Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. Neurol Res. 2015. 37:619–623. DOI:
doi: 10.1179/1743132815Y.0000000021.
Article
3.Liu JS., Chuang TJ., Chen JH., Lee CH., Hsieh CH., Lin TK, et al. Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products. Endocrine. 2015. 49:703–710. DOI:
doi: 10.1007/s12020-015-0545-6.
Article
4.Tanaka T., Ishikawa T., Hagiwara M., Onoda K., Itoh H., Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology. 1988. 36:313–320.
Article
5.Dawson DL., Cutler BS., Meissner MH., Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication. Results from a multi-center, randomized, prospective, double-blind trial. Circulation. 1998. 98:678–686.
Article
6.Dawson DL., Cutler BS., Hiatt WR., Hobson RW 2nd., Martin JD., Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J med Med. 2000. 109:523–530.
Article
7.Shin KH., Yoon G., Yoon IS., Park JW. Preparation and evaluation of oral controlled-release cilostazol formulation: pharmacokinetics and antithrombotic efficacy in dogs and healthy male Korean participants. J Pharm Pharmacol. 2014. 66:961–974. DOI:
doi: 10.1111/jphp.12227.
Article
8.Karalis V., Macheras P. Examining the role of metabolites in bioequivalence assessment. J Pharm Pharm Sci. 2010. 13:198–217.
Article
9.Srinivas NR. Considerations for metabolite pharmacokinetic data in bioavail-ability/bioequivalence assessments. Overview of the recent trends. Arzneimit-telforschung. 2009. 59:155–165. DOI:
doi: 10.1055/s-0031-1296380.
10.Jackson AJ., Robbie G., Marroum P. Metabolites and bioequivalence: past and present. Clin Pharmacokinet. 2004. 43:655–672.
11.Kim HS., Kim GY., Yeo CW., Oh MK., Ghim JL., Shon JH, et al. The effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects. Br J Clin Pharmacol. 2014. 77:821–830. DOI:
doi: 10.1111/bcp.12236.
12.Kim YH., Ghim JL., Jung JA., Cho SH., Choe S., Choi HY, et al. Pharmacokinetic comparison of sustained- and immediate-release formulations of cilostazol after multiple oral doses in fed healthy male Korean volunteers. Drug Des Devel Ther. 2015. 9:3571–3577. DOI:
doi: 10.2147/DDDT.S86845.
13.Woo SK., Kang WK., Kwon KI. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiov ascular effects of cilostazol in healthy humans. Clin Pharmacol Ther. 2002. 71:246–252.